Root Financial Partners LLC Buys New Position in AstraZeneca PLC $AZNCF

Root Financial Partners LLC bought a new stake in AstraZeneca PLC (OTCMKTS:AZNCF) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 3,547 shares of the company’s stock, valued at approximately $622,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AZNCF. Twin Peaks Wealth Advisors LLC acquired a new stake in AstraZeneca in the 4th quarter valued at about $208,000. Bearing Point Capital LLC acquired a new stake in AstraZeneca in the 4th quarter valued at about $2,047,000. Rothschild Investment LLC acquired a new stake in AstraZeneca in the 4th quarter valued at about $200,000. Thoroughbred Financial Services LLC acquired a new stake in AstraZeneca in the 4th quarter valued at about $1,487,000. Finally, Cary Street Partners Investment Advisory LLC acquired a new stake in AstraZeneca in the 4th quarter valued at about $412,000. Institutional investors own 40.87% of the company’s stock.

AstraZeneca Price Performance

Shares of OTCMKTS AZNCF opened at $187.10 on Wednesday. AstraZeneca PLC has a twelve month low of $122.26 and a twelve month high of $195.00. The firm has a 50-day moving average of $187.10 and a two-hundred day moving average of $185.42.

AstraZeneca Company Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.